The purpose of the trial is to find out whether adding orelabrutinib to the usual regimen can keep the disease from getting worse for a longer period of time. After a screening visit, participants are randomly assigned to one of the two groups, and neither the participants nor the doctors know which group they are in. Treatment is given in repeated cycles over several months, with regular check‑ups that include blood tests, heart checks, and questionnaires about quality of life. The study follows participants for several years to see how long they stay free of disease progression and to monitor safety.

The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The aim is to see if adding Panzyga can lower the chance of a major infection or death in this vulnerable group. Participants will receive the assigned infusion once every few weeks for several months, and they will be checked regularly by doctors for any signs of infection, side effects, or changes in health. The study is set up so that neither the participants nor the doctors know which infusion is being given, to keep the comparison fair.

Throughout the trial, any infection that occurs will be recorded, and an independent group of experts will decide whether it meets the definition of a major infection. Safety will also be monitored by looking at reported side effects and routine lab tests. The information gathered will help determine whether the treatment is safe and effective for preventing serious infections in people with weak immune systems due to their underlying disease and therapy.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

During the study, the effectiveness of tulisokibart will be monitored over a period of time. The investigation looks at how many people reach clinical remission, a state where the symptoms of the disease are significantly reduced or absent. Researchers will also observe endoscopic improvement, which refers to visible healing of the intestinal lining during a procedure where a camera is used to look inside the body, and histologic-endoscopic mucosal improvement, which means the tissue appears healthy both under a microscope and during a visual examination.

The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.

During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.

The main purpose of this research is to determine if Xeomin is more effective than placebo in reducing the number of monthly migraine days. The study involves different doses of the medication, with participants receiving either Xeomin or placebo injections. The treatment period lasts for 6 months, during which participants will receive multiple injections.

The medication being tested, Xeomin, is a purified form of botulinum toxin that is free from complexing proteins. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of acute migraine medications. Throughout the study, participants will need to keep track of their migraine episodes and any changes in their condition.

The treatment will involve receiving regular injections of the study medications for up to 52 weeks. Mirikizumab is a type of medication called a monoclonal antibody, which works by targeting specific parts of the immune system. Tirzepatide is a medication that can help with weight management. Some participants will receive both active medications, while others will receive Mirikizumab with placebo.

The study will measure how many participants achieve two goals at the same time: improvement in their Ulcerative Colitis symptoms and a significant reduction in their body weight. The medications will be given through injections either under the skin or into a vein, depending on the specific medication being administered.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of itepekimab in adults who have chronic rhinosinusitis with nasal polyps that are not well controlled. Participants in the study will receive either itepekimab or a placebo through an injection once a week for a total of 52 weeks, which is about one year. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if itepekimab can help reduce the symptoms of nasal polyps and improve the quality of life for those affected by this condition.

By participating in this study, researchers hope to gather important information about how itepekimab can help people with chronic rhinosinusitis with nasal polyps. This could lead to better treatment options in the future for those suffering from this condition. The study will also monitor any side effects or adverse reactions to ensure the safety of the participants. The results of this study could provide valuable insights into managing and treating chronic rhinosinusitis with nasal polyps more effectively.

The purpose of the study is to evaluate how effective and safe guselkumab is for people with moderately to severely active ulcerative colitis. Participants in the study will receive either the medication or a placebo. The study will last for a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment.

Throughout the study, researchers will assess whether participants achieve clinical remission, which means a significant reduction or disappearance of symptoms. The study aims to provide valuable information about the potential benefits of guselkumab for individuals living with ulcerative colitis.

The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

Participants in the study will receive a combination of medications. One group will take RO7771950 along with trastuzumab and capecitabine. The other group will receive tucatinib combined with trastuzumab and capecitabine. The trastuzumab may be given through an IV infusion, which is a liquid medicine delivered directly into a vein, or as a subcutaneous injection, which is administered just under the skin. The other medications are taken as an oral tablet by mouth.

During the study, medical professionals will monitor how the treatments affect the cancer and how the body responds over time. The research will look at how long the cancer stays stable without growing, a measure known as progression-free survival. Other aspects of the study include monitoring overall survival, how much the tumors shrink, and any side effects experienced during the treatment period.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

During the study, participants will take these medications as part of a treatment plan. The process involves monitoring the disease to see how the body responds to the combined medicines. The study will follow the participants over time to see how long the treatment keeps the cancer under control and to ensure the medications are being used safely.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The purpose of this study is to find out if treatment with linvoseltamab alone or linvoseltamab combined with carfilzomib works better than standard treatments for multiple myeloma that has returned or stopped responding to previous therapy. The study will measure how many patients have no signs of cancer cells remaining in their body after twelve months of treatment and how long patients live without their cancer getting worse. The study will also look at how safe these treatments are and what side effects patients may experience.

The study has two parts. In the first part, a small number of patients will receive linvoseltamab or linvoseltamab with carfilzomib to check that the dosing schedule is safe. In the second part, a larger group of patients will be randomly assigned to receive either linvoseltamab alone, linvoseltamab with carfilzomib, or standard treatment combinations. Patients will receive their assigned treatment in cycles lasting twenty-eight days. During the study, patients will have regular check-ups, blood tests, and other examinations to see how well the treatment is working and to monitor for any side effects. The study will also ask patients questions about their quality of life and how they are feeling.

The purpose of this study is to assess the long-term safety and tolerability of Navenibart in people with Hereditary Angioedema. The study will also look at how well the medication works in preventing swelling attacks over an extended period of time. Participants in this study will be people who previously took part in another study called STAR-0215-301 and either completed that study or received at least two doses of the medication and were followed for at least two months after the second dose.

During the study, participants will receive regular doses of the medication, with a maximum daily dose of 600 milligrams and a total maximum dose of 9600 milligrams over a treatment period of up to 48 weeks. The study will track any side effects or health problems that occur during treatment. Researchers will also count how many swelling attacks participants experience, including how many are moderate or severe, and how many require emergency treatment. The study will measure whether participants have fewer attacks compared to before treatment, including whether they achieve reductions of 50 percent, 70 percent, or 90 percent in their attack rate, or whether they have no attacks at all. Quality of life will be measured using a questionnaire specifically designed for people with swelling conditions.

The study is divided into different parts. People who join this particular part of the study will be those who have already shown improvement after earlier treatment and have completed certain examinations. The study will look at whether Duvakitug can help keep the condition in a state where symptoms are minimal or absent, which is called remission. During the study, doctors will check the condition of the intestine using an examination that looks inside the bowel, and they will also assess symptoms such as bowel movements, bleeding, and abdominal pain. The study will also look at whether people can stop using steroid medications while maintaining good control of their condition.

Throughout the study, participants will be monitored for any side effects or unwanted reactions to the treatment. The study will measure various aspects of the disease and how it affects daily life, including fatigue levels, quality of life, and the need for hospital care related to ulcerative colitis. Blood samples will be taken to measure the amount of Duvakitug in the body and to check if the body develops any immune response to the medication. The study will also include a longer extension period for people who complete the main part of the study, allowing for continued observation of the medication’s effects and safety over time.

The purpose of this study is to assess how well Duvakitug works as an initial treatment for moderately to severely active Ulcerative Colitis compared to placebo. The study will look at whether the medication can help reduce symptoms and inflammation in the intestines. This is called an induction study, which means it focuses on the first phase of treatment to see if the medication can bring the disease under control.

The study will measure several outcomes to determine if the treatment is working. The main outcome will be the proportion of participants who achieve clinical remission, which means their symptoms have improved significantly or disappeared. Other outcomes include improvements in the appearance of the intestine lining as seen during examination, reduction in symptoms like bowel urgency and abdominal pain, improvements in quality of life, and whether participants need to be hospitalized due to their condition. The study will also monitor any side effects and measure the levels of the medication in the blood over time. The treatment period will last up to 24 weeks.

During the study, participants will receive treatment for up to 12 months. The researchers will measure several things to see if the treatment is helping, including changes in body weight and appetite over a 12-week period. Body weight will be tracked from the beginning of the study, and appetite will be measured using a questionnaire that asks specific questions about eating and food-related concerns. The study will also look at muscle mass using imaging scans such as CT or MRI, which are types of medical imaging that create detailed pictures of the inside of the body. Physical function will be tested through simple exercises like a chair stand test, and daily physical activity levels will be monitored.

Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. Participants will also complete questionnaires about their quality of life, how severe their symptoms are, and whether they notice any changes in their condition. Blood samples will be taken to measure the levels of the medication in the body. The study will track overall health outcomes and how the cancer responds to ongoing treatment during this time.

Participants in this study will be randomly assigned to receive either ivonescimab or bevacizumab, both given in combination with FOLFOX chemotherapy. The study is designed so that neither the participants nor their doctors will know which treatment is being given, which helps ensure fair comparison of the results. The medications will be given through a vein, which means they are delivered directly into the bloodstream through an intravenous line. During the study, participants will have regular check-ups where doctors will monitor the size of tumors using imaging scans and assess how well the treatment is working. The study will also track any side effects that occur and measure the levels of ivonescimab in the blood at different times.

The study will also collect information about how long participants live overall, how many people respond to treatment, and how long those responses last. Doctors will monitor for any unwanted effects from the medications and check blood tests for abnormal results. For those receiving ivonescimab, the study will also check whether the body develops antibodies against this medication, which could affect how well it works. This study is intended for people who have not yet received treatment for their metastatic colorectal cancer, though previous treatment for earlier stages of the disease is allowed if it was completed more than twelve months before the cancer spread.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The purpose of this study is to find out whether tislelizumab given as an injection under the skin reaches the same levels in the body as when it is given through a vein, and to see if the injection under the skin is as safe and effective as the intravenous method. The study will measure the amount of medication in the blood at different times and compare the results between the two groups. Researchers will also look at how well the treatment works by checking whether tumors shrink or stop growing, how long patients live without their cancer getting worse, and how long the treatment keeps working.

During the study, patients will receive tislelizumab in one of the two ways mentioned, along with chemotherapy, as their first treatment for this type of advanced cancer. The treatment can continue for up to 24 months. Throughout the study, doctors will monitor patients for any side effects and collect information about how the cancer responds to treatment. Patients will need to provide tumor tissue samples for testing, and the study will also check whether the body develops any immune responses against the medication.

The purpose of this study is to compare how well the combination of belzutifan and zanzalintinib works against cabozantinib in treating advanced kidney cancer. The study will look at how long people live without their cancer getting worse and how long they live overall. The study will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long that response lasts.

During the study, people will be randomly assigned to receive either the combination treatment or cabozantinib alone. The study will track any unwanted effects that occur and whether people need to stop treatment because of these effects. The study will also measure quality of life and how well people are able to carry out daily activities using questionnaires that ask about physical health, ability to perform usual activities, and symptoms related to kidney cancer. The study will continue to follow people over time to gather information about how the treatments affect their cancer and overall health.

The study is designed so that participants will be randomly assigned to receive either ADX-324 or placebo. The study is double-blind, which means that neither the participants nor the doctors will know who is receiving the actual medication or placebo during the treatment period. Before starting the treatment, there will be a screening period lasting up to eight weeks to confirm that participants have the right type of condition and experience swelling attacks frequently enough to be part of the study. During this screening time, doctors will check medical history and confirm the diagnosis through specific blood tests that measure certain proteins and complement levels in the blood.

The treatment period will last for 25 weeks, during which participants will receive regular injections of either ADX-324 or sterile normal saline, which is the placebo. Throughout the study, participants will need to keep track of any swelling attacks they experience and will have access to rescue medication that they have used before to treat attacks when they occur. The study will measure how many swelling attacks occur during the treatment period, how many attacks require the use of rescue medication, and how many participants remain free from attacks. Doctors will also look at the severity of any attacks that do occur and compare the results between those receiving ADX-324 and those receiving placebo.

The treatment involves using inhalation powder contained in hard capsules that are breathed in through a special inhaler device. Some participants will receive PHENOGENE-1a, while others will receive placebo through the same type of inhaler. The maximum daily amount of medication is 64.8 mg, and treatment continues for 24 weeks.

During the study, participants will need to continue taking their regular ALS medication called riluzole. The study will monitor various aspects of the disease, including breathing function and overall physical abilities. All participants must be between 18 and 75 years old and have been diagnosed with ALS within the past 24 months.

The purpose of the study is to determine if adding ficerafusp alfa to pembrolizumab works better than pembrolizumab with placebo for patients who have not received previous treatment for their advanced cancer. The study will test two different doses of ficerafusp alfa (750 mg and 1500 mg) to find the most effective and safest dose when combined with pembrolizumab.

During the treatment, participants will receive regular doses of the study medications for up to 24 months. The study will track how well the treatment works by measuring if the cancer shrinks or disappears (tumor response), how long patients live (overall survival), and how long patients live without their cancer getting worse (progression-free survival). The study will also monitor any side effects that participants may experience during treatment.